Publications by authors named "W Ghesquiere"
Article Synopsis
- This study examines the long-term effectiveness and immune responses of the recombinant zoster vaccine (RZV) in adults aged 50 and older, focusing on data collected 5 to 7 years after vaccination.
- Analysis included 7,413 participants, revealing a sustained efficacy rate against herpes zoster (HZ) of approximately 84% to 90% from both the start of follow-up and from the original trials, with stable results over the years.
- Immune responses, measured by antibody concentrations and specific T-cell frequencies, showed significant persistence, indicating that the benefits of RZV for older adults last at least 7 years post-vaccination.
Background: Due to ongoing political instability and conflict in many parts of the world, migrants are increasingly seeking asylum and refuge in Canada.
Methods: We examined demographic and travel correlates of illnesses among migrants to Canada to establish a detailed epidemiologic framework of this population for Canadian practitioners. Data on ill-returned Canadian travellers presenting to a CanTravNet site between 1 January 2015 and 31 December 2015 were analyzed.
Background: Optimal treatment for patients with HCV genotype-3 infection and liver cirrhosis remains a medical priority. Daclatasvir+sofosbuvir and ribavirin is a recommended option for such patients, but clinical trial data are lacking for treatment >16 weeks.
Methods: This was a single-arm, Phase III study of daclatasvir+sofosbuvir+ribavirin for 24 weeks in patients with compensated cirrhosis and HCV genotype-3 infection.
Background & Aims: Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long-term efficacy and safety of daclatasvir-based regimens administered during clinical studies.
Methods: Patients enrolled within 6 months of parent study completion or protocol availability at the study sites.